Diagnosis and management of dementia with Lewy bodies

Fourth consensus report of the DLB Consortium

ABSTRACT

The Dementia with Lewy Bodies (DLB) Consortium has refined its recommendations about the clinical and pathologic diagnosis of DLB, updating the previous report, which has been in widespread use for the last decade. The revised DLB consensus criteria now distinguish clearly between clinical features and diagnostic biomarkers, and give guidance about optimal methods to establish and interpret these. Substantial new information has been incorporated about previously reported aspects of DLB, with increased diagnostic weighting given to REM sleep behavior disorder and $^{123}$I-metaiodobenzylguanidine (MIBG) myocardial scintigraphy. The diagnostic role of other neuroimaging, electrophysiologic, and laboratory investigations is also described. Minor modifications to pathologic methods and criteria are recommended to take account of Alzheimer disease neuropathologic change, to add previously omitted Lewy-related pathology categories, and to include assessments for substantia nigra neuronal loss. Recommendations about clinical management are largely based upon expert opinion since randomized controlled trials in DLB are few. Substantial progress has been made since the previous report in the detection and recognition of DLB as a common and important clinical disorder. During that period it has been incorporated into DSM-5, as major neurocognitive disorder with Lewy bodies. There remains a pressing need to understand the underlying neuropsychobiology and pathophysiology of DLB, to develop and deliver clinical trials with both symptomatic and disease-modifying agents, and to help patients and carers worldwide to inform themselves about the disease, its prognosis, best available treatments, ongoing research, and how to get adequate support. Neurology® 2017;89:88-100

GLOSSARY

AD = Alzheimer disease; CHEI = cholinesterase inhibitor; DAT = dopamine transporter; DLB = dementia with Lewy bodies; DSM-5 = Diagnostic and Statistical Manual of Mental Disorders, 5th edition; LB = Lewy body; MCI = mild cognitive impairment; MIBG = metaiodobenzylguanidine; MMSE = Mini-Mental State Examination; MTL = medial temporal lobe; PD = Parkinson disease; PSG = polysomnography; RBD = REM sleep behavior disorder.

The Dementia with Lewy Bodies (DLB) Consortium last reported on diagnosis and management in December 2005, and its recommendations have been widely cited for both clinical and research use. Changes made to the diagnostic criteria at that time increased diagnostic sensitivity for DLB, but detection rates in clinical practice remain suboptimal, with many cases missed or misdiagnosed, usually as Alzheimer disease (AD). The revised DLB criteria presented here incorporate new developments since then and result from a review process that combined the reports of 4 multidisciplinary, expert working groups with a meeting that included patient and care partner participation (appendix e-1 at Neurology.org). The Consortium recognizes increasing interest in detecting early-stage disease; prodromal DLB criteria are in development and will be reported separately.

SUMMARY OF CHANGES While maintaining their previous structure, the revised DLB clinical diagnostic criteria improve on earlier versions by distinguishing clearly between clinical features and diagnostic

Author affiliations are provided at the end of the article.

Members of the DLB Consortium are listed at Neurology.org.

Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

The Article Processing Charge was paid by NIHR Newcastle Biomedical Research Centre in Ageing and Long-Term Conditions.

This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Dementia, defined as a progressive cognitive decline of sufficient magnitude to interfere with normal social or occupational functions, or with usual daily activities, is an essential requirement for DLB diagnosis. Although dementia screens such as the Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment are useful to characterize global impairment in DLB, neuropsychological assessment should include tests covering the full range of cognitive domains potentially affected. Disproportionate attentional, executive function, and visual processing deficits relative to memory and naming are typical e4–6 Measures of attention/executive function that differentiate DLB from AD and normal aging and that predict progression from mild cognitive impairment (MCI) to DLB include tests of processing speed and divided/alternating attention, e.g., Stroop tasks, trail-making tasks, phonemic fluency, and computerized tasks of reaction time. The spatial and perceptual difficulties of DLB often occur early; examples of useful probes include tasks of figure copy, e.g., intersecting pentagons, complex figure copy; visual assembly, e.g., block design, puzzle tasks; spatial matching, e.g., line orientation, size matching tasks; and perceptual discrimination, e.g., incomplete figures, incomplete letters, pareidolia tasks.10,14

Memory and object naming tend to be less affected in DLB, and are best evaluated through story recall, verbal list learning, and confrontation naming tasks, although some patients’ difficulties may be secondary to speed or retrieval task demands.

No DLB-specific assessment batteries have been developed, although recommendations have been made about suitable existing instruments11 and a composite risk score tool has been published.12

Core clinical features. Fluctuation. DLB fluctuations have been described in detail previously1–2 and are typically delirium-like, occurring as spontaneous alterations in cognition, attention, and arousal. They include waxing and waning episodes of behavioral inconsistency, incoherent speech, variable attention, or altered consciousness that involves staring or zoning out. Direct questioning of an informant about fluctuations may not reliably discriminate DLB from AD, but questions about daytime drowsiness, lethargy, staring into space, or episodes of disorganized speech do. These have been incorporated into scales that either score the severity and frequency of fluctuations derived from a clinical interview or use informant reports from semi-structured questionnaires.11–16 Recording variations in attentional performance using repeated computer-based tests offers an independent method.17 At least one measure of fluctuation should be documented when applying DLB diagnostic criteria. Fluctuations may also occur in advanced stages of other dementias, so they best predict DLB when they are present early.17

Visual hallucinations. Recurrent, complex visual hallucinations occur in up to 80% of patients with DLB and are a frequent clinical signpost to diagnosis. They are typically well-formed, featuring people, children, or animals, sometimes accompanied by related phenomena including passage hallucinations, sense of presence, and visual illusions.18 Patients are typically able to report these experiences, as are observant caregivers. Patient responses to their hallucinations vary both in degree of insight and emotional reaction to them. Assessment scales for characterizing and quantifying visual hallucinations are available.17

Parkinsonism. Spontaneous parkinsonian features, not due to antiparkinsonian medications or stroke, are common in DLB, eventually occurring in over 85%.19 Parkinsonism in Parkinson disease (PD) is defined as bradykinesia in combination with rest tremor, rigidity, or both.19 Many DLB patients’ parkinsonism falls short of this, so documentation of only one of these cardinal features is required. Care should be taken particularly in older patients not to misinterpret physical signs due to comorbidity, e.g.,
Table 1 Revised criteria for the clinical diagnosis of probable and possible dementia with Lewy bodies (DLB)

<table>
<thead>
<tr>
<th>Probable DLB</th>
<th>Possible DLB</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Core clinical features</strong> (The first 3 typically occur early and may persist throughout the course.)</td>
<td></td>
</tr>
<tr>
<td>Fluctuating cognition with pronounced variations in attention and alertness.</td>
<td></td>
</tr>
<tr>
<td>REM sleep behavior disorder, which may precede cognitive decline.</td>
<td></td>
</tr>
<tr>
<td>One or more more indicative biomarkers of parkinsonism: these are bradykinesia (defined as slowness of movement and decrement in amplitude or speed), rest tremor, or rigidity.</td>
<td></td>
</tr>
<tr>
<td><strong>Supportive clinical features</strong></td>
<td></td>
</tr>
<tr>
<td>Severe sensitivity to antipsychotic agents; postural instability; repeated falls; syncope or other transient episodes of unresponsiveness; severe autonomic dysfunction, e.g., constipation, orthostatic hypotension, urinary incontinence; hypopnoea; hyposmia; hallucinations in other modalities; systematized delusions; apathy, anxiety, and depression.</td>
<td></td>
</tr>
<tr>
<td><strong>Indicative biomarkers</strong></td>
<td></td>
</tr>
<tr>
<td>Reduced dopamine transporter uptake in basal ganglia demonstrated by SPECT or PET.</td>
<td></td>
</tr>
<tr>
<td><strong>Supportive biomarkers</strong></td>
<td></td>
</tr>
<tr>
<td>Polysomnographic confirmation of REM sleep without atonia.</td>
<td></td>
</tr>
<tr>
<td><strong>Probable DLB</strong> can be diagnosed if:</td>
<td></td>
</tr>
<tr>
<td>a. Two or more core clinical features of DLB are present, with or without the presence of indicative biomarkers, or</td>
<td></td>
</tr>
<tr>
<td>b. Only one core clinical feature is present, but with one or more indicative biomarkers.</td>
<td></td>
</tr>
<tr>
<td><strong>Probable DLB</strong> should not be diagnosed on the basis of biomarkers alone.</td>
<td></td>
</tr>
<tr>
<td><strong>Possible DLB</strong> can be diagnosed if:</td>
<td></td>
</tr>
<tr>
<td>a. Only one core clinical feature of DLB is present, with no indicative biomarker evidence, or</td>
<td></td>
</tr>
<tr>
<td>b. One or more indicative biomarkers is present but there are no core clinical features.</td>
<td></td>
</tr>
<tr>
<td><strong>DLB</strong> is less likely:</td>
<td></td>
</tr>
<tr>
<td>a. In the presence of any other physical illness or brain disorder including cerebrovascular disease, sufficient to account in part or in total for the clinical picture, although these do not exclude a DLB diagnosis and may serve to indicate mixed or multiple pathologies contributing to the clinical presentation, or</td>
<td></td>
</tr>
<tr>
<td>b. If parkinsonian features are the only core clinical feature and appear for the first time at a stage of severe dementia.</td>
<td></td>
</tr>
<tr>
<td>DLB should be diagnosed when dementia occurs before or concurrently with parkinsonism. The term Parkinson disease dementia (PDD) should be used to describe dementia that occurs in the context of well-established Parkinson disease. In a practice setting the term that is most appropriate to the clinical situation should be used and generic terms such as Lewy body disease are often helpful. In research studies in which distinction needs to be made between DLB and PDD, the existing 1-year rule between the onset of dementia and parkinsonism continues to be recommended.</td>
<td></td>
</tr>
</tbody>
</table>
either because of minimal brainstem involvement and limited nigral neuron loss\textsuperscript{27} or a balanced loss of dopamine across the whole striatum, rather than predominantly in the putamen.

Reduced uptake on metaiodobenzylguanidine myocardial scintigraphy

\textsuperscript{123}Iodine-MIBG myocardial scintigraphy quantifies postganglionic sympathetic cardiac innervation, which is reduced in LB disease.\textsuperscript{12,24-26} Images from patients with AD, DLB, and age-matched normal controls are shown in figure 2. Useful sensitivity (69\%) and specificity (87\%) values for discriminating probable DLB from probable AD rise to 77\% and 94\% in milder cases (MMSE \textgreater{}21).\textsuperscript{28} Studies have generally excluded patients with comorbidities, or taking medicines, which can produce abnormal MIBG images. Clinicians should carefully interpret MIBG results in the light of possible confounding causes, including ischemic heart disease, heart failure, diabetes mellitus, peripheral neuropathies, and medications that may cause reduced uptake including labetalol, reserpine, tricyclic antidepressants, and over-the-counter sympathomimetics.\textsuperscript{29,14,15}

PSG confirmation of REM sleep without atonia. PSG demonstration of REM sleep without atonia\textsuperscript{16-17} is desirable whenever feasible, since it is a highly specific predictor of Lewy-related pathology. If the PSG shows REM sleep without atonia in a person with dementia and a history of RBD, there is a \geq90\% likelihood of a synucleinopathy,\textsuperscript{22} sufficient to justify a probable DLB diagnosis even in the absence of any other core feature or biomarker (figure 3).

Supportive biomarkers. These are biomarkers consistent with DLB that help the diagnostic evaluation, but without clear diagnostic specificity.

Relative preservation of medial temporal lobe structures on CT/MRI scan. Patients with AD show greater atrophy of medial temporal lobe (MTL) structures than patients with DLB (figure 1), particularly the hippocampus, which is strongly correlated at autopsy with tangle rather than plaque or LB-related pathology.\textsuperscript{30} Absent or minimal MTL atrophy is therefore consistent with DLB, but unusual in AD. A multisite study with autopsy confirmation found sensitivity (64\%) and specificity (68\%) for separating AD from DLB.\textsuperscript{31} MTL atrophy in DLB may, however, signal substantial additional AD neuropathologic change, and predict a more rapid clinical course.\textsuperscript{32}

Generalized low uptake on SPECT/PET perfusion/metabolism scan, reduced occipital activity, and the posterior cingulate island sign on FDG-PET imaging. FDG-PET occipital hypometabolism correlates with visual cortex neuropathology in DLB\textsuperscript{33} and a small, autopsy-confirmed study suggested this could distinguish DLB from AD with
Larger studies, earlier in disease, suggest sensitivity (70%) and specificity (74%) slightly lower than needed for an indicative biomarker, although better than that reported for HMPAO-SPECT (65% and 64%). Relative preservation of posterior or midcingulate metabolism on FDG-PET (the cingulate island sign) has been described in DLB, associated with less concurrent neurofibrillary pathology, but with no difference in Aβ load relative to AD (figure 4).

Evidence is building to support quantitative EEG as a DLB biomarker, characterized by specific abnormalities in posterior derivations. These include a pre-alpha-dominant frequency, either stable or intermixed with alpha/theta/delta activities in pseudoperiodic patterns, which together have a predictive value >90% for the diagnosis of DLB compared with AD. These specific EEG patterns also correlate positively with the severity of clinically observed cognitive fluctuations and may be seen at the MCI stage.

Other imaging biomarkers. PET imaging shows increased Aβ brain deposition in >50% of patients with DLB, limiting its value to distinguish between AD and DLB. Combining biomarkers in a multimodal approach can improve diagnostic accuracy in distinguishing DLB and AD and provides information about mixed pathology and multisystem involvement. Tau PET imaging may have an important role, along with MTL atrophy, as a key indicator of coexisting AD pathology in DLB, predictive of clinical phenotype and progression.

Genetic and fluid biomarkers. The development of broadly applicable CSF, blood, peripheral tissue, or genotypic biomarkers for DLB remains elusive. Although it is clear that there is a substantial genetic contribution to DLB and that different genetic markers even within the alpha-synuclein gene (SNCA) may be associated with different LB syndromes, our understanding of the core genes involved remains limited. CSF α-synuclein is not yet proven as a biomarker, while Aβ, tau, and phospho-tau measurements may be more useful in determining concomitant AD pathology or predicting cognitive decline. Glucocerebrosidase (GBA) mutations are overrepresented in DLB but most individuals with DLB do not have them. It is premature to recommend genetic testing in a clinical setting, either for confirmation of diagnosis or for prediction of disease, and genetic studies should currently be limited to research settings.
Clinical management. The management of patients with DLB is complex, requiring a multifaceted approach. Key elements include a thorough initial evaluation to ensure accurate diagnosis; early identification of signs and symptoms requiring intervention; engagement, education, and support of care providers; and a multidisciplinary team approach. Patients with DLB are prone to mental status worsening, including delirium, in the face of comorbid medical disorders. Dopaminergic therapies and anticholinergic medications can adversely affect cognition and behavior, leading to confusion and psychosis.18,19 Treatment of DLB is focused on the cognitive, psychiatric, motor, and other nonmotor symptoms that represent the core or most common features of the disorder.45 A combination of pharmacologic and nonpharmacologic approaches is optimal. As the evidence base to support particular treatments remains limited, the recommendations outlined below remain based, in part, upon consensus expert opinion.

Nonpharmacologic interventions. Given both the limited evidence for efficacy and the potential increased morbidity and mortality risks associated with pharmacologic treatments in DLB, there is a need to develop and test nonpharmacologic management strategies. Interventions can be patient- or caregiver-focused, or both. More research in this area has been conducted in AD and PD than in DLB, with promising preliminary evidence for exercise (both motor and cognitive benefits),46 cognitive training,18 and caregiver-oriented education and training to manage psychiatric symptoms including agitation and psychosis.18,19

Pharmacologic management. Cognitive symptoms. Meta-analyses of Class I clinical trials of rivastigmine and donepezil support the use of cholinesterase inhibitors (CHEIs) in DLB for improving cognition, global function, and activities of living, with evidence that even if patients do not improve with CHEIs they are less likely to deteriorate while taking them.47,48 The efficacy of memantine in DLB is less clear, but it is well-tolerated and may have benefits, either as monotherapy or adjunctive to a CHEI.47,48

Neuropsychiatric symptoms. CHEIs may produce substantial reduction in apathy and improve visual...
hallucinations and delusions in DLB.49 Since anxiety and agitation are sometimes driven by psychosis, there may be secondary benefits in these. The use of antipsychotics for the acute management of substantial behavioral disturbance, delusions, or visual hallucinations comes with attendant mortality risks in patients with dementia, and particularly in the case of DLB they should be avoided whenever possible, given the increased risk of a serious sensitivity reaction.50 Low-dosequetiapine may be relatively safer than other antipsychotics and is widely used, but a small placebo-controlled clinical trial in DLB was negative.51 There is a positive evidence based for clozapine in PD psychosis, but efficacy and tolerability in DLB have not been established. Newer drugs targeting the serotonergic system, such as pemuranserin,52 may be alternatives, but controlled clinical trial data in DLB are needed. Although depressive symptoms are common in DLB, trial data are scant. In alignment with general advice on depression in dementia, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and mirtazapine are options in DLB with treatment guided by individual patient tolerability and response.

Motor symptoms. Parkinsonism is often less responsive to dopaminergic treatments in DLB than in PD and their use may be associated with an increased risk of psychosis, although some patients may benefit from levodopa preparations introduced at low doses and increased slowly to the minimum required to minimize motor disability without exacerbating psychiatric symptoms.53,e28 Patients at risk of falling may benefit from safety assessments, as well as bone mineral density screening, and assessment of vitamin D status, to manage risk of traumatic fractures.

Other symptoms. A wide range of other symptoms can occur in DLB, including autonomic and sleep/wakefulness disturbances, which have profound negative sequelae for quality of life in both patients and their families. In the absence of DLB-specific trial data for these symptoms, clinicians base their treatment decisions on clinical experience, expert opinion, or evidence-based recommendations developed in other diseases, e.g., cautious bedtime use of clonazepam may reduce the risk of sleep-related injuries in

---

Figure 4 18F-FDG-PET images in Alzheimer disease (AD), dementia with Lewy bodies (DLB), and normal controls (NC)

(A) Right lateral metabolic surface map projection. (B) Standard axial view transecting the posterior cingulate region. Occipital lobe metabolism is preserved in AD and NC but reduced (blue arrows) in DLB. Hypometabolism in AD is predominantly in the temporal, parietal, and frontal regions. There is normal metabolism as reflected by the normal 18F-FDG uptake (lighter shade of gray) in the posterior cingulate region (yellow arrowhead) surrounded by reduced 18F-FDG uptake (darker gray) in the adjacent occipital cortex in DLB, representing the cingulate island sign. This contrasts with the relatively reduced 18F-FDG uptake in the posterior cingulate and relatively preserved 18F-FDG uptake in the occipital cortex regions in AD. In the control, there is normal 18F-FDG uptake in the posterior cingulate, occipital, and other neocortical regions. Color and grayscale sidebars show increasing degrees of deviation from normal as the signal trends lower in the sidebars (red is normal while black is maximally abnormal in color images; white is normal while black is maximally abnormal in grayscale images). Reproduced with permission from Dr. Val Lowe, Mayo Clinic, Rochester, MN.
patients with DLB with RBD but carries a risk of worsening cognition and gait impairment, melatonin being a possibly safer option.

Pathology. Pathologic assessment and diagnostic criteria for DLB. The previously published methods for pathologic assessment and diagnosis of DLB should continue to be used with only a few modifications, shown in Table 2, which predicts the likelihood that the pathologic findings will be associated with a typical DLB clinical syndrome, i.e., cases with high likelihood are expected to fulfill clinical criteria for probable DLB, whereas low likelihood cases may have few or no DLB clinical features.

Table 2 assigns categories of AD neuropathologic change according to National Institute on Aging–Alzheimer’s Association criteria (no, low, intermediate, and high), and adds previously omitted categories of Lewy-related pathology including olfactory bulb only and amygdala predominant. Both of these are considered to be low-likelihood DLB but may in the future be useful in assessing prodromal disease. Further efforts are required to develop better interrater reliability for Lewy-related disease subtypes (olfactory bulb only, amygdala predominant, brainstem, limbic [transitional], and diffuse neocortical). Table 2 also includes an assessment of substantia nigra neuronal loss (none, mild, moderate, and severe) in order to subclassify cases into those likely or not to have parkinsonism (DLB-P and DLB-no P).

FUTURE DIRECTIONS. Since publication of the 2005 consensus report, DLB has been confirmed as a major dementia subtype, categorized in DSM-5 as neurocognitive disorder with LB, and distinguished from neurocognitive disorder due to PD. The consensus group remains supportive of the 1-year rule distinguishing DLB from PD dementia, because as originally stated, this arbitrary cutoff remains useful, particularly in clinical practice. Based as it is on expert opinion, the time period may need modification when the genetic underpinnings, pathophysiologic mechanisms, and prodromal states of these disorders are sufficiently understood to enable a data-driven solution.

There is an urgent need to develop guidelines and outcome measures for clinical trials in DLB, both symptomatic and disease-modifying, nonpharmacologic and pharmacologic. DLB researchers can build upon experience gained in AD and PD; additional issues for them to consider include subtyping of patients on the basis of clinical or biomarker criteria and selecting target symptoms and outcome measures appropriate to DLB. It will be necessary to manage potential confounding factors that are common in DLB, e.g., fluctuations in alertness and fatigue, active hallucinations, and concomitant use of cognitive enhancing and psychiatric medications. Such considerations will need to be applied when designing clinical trials across the spectrum of clinical syndromes of DLB from prodromal and presymptomatic stages, still to be identified, to overt dementia.

Suggested strategies to progress critical areas of biological research include collecting samples from large population-based cohorts and developing a publicly available DLB genetic database and a repository for DLB exome data. Family studies are needed to find and confirm genes, requiring clinicians to take detailed family histories seeking evidence not only of DLB, PD, and AD and other dementias, but also of RBD and supportive features.

In order to make progress in deciphering biological mechanisms at play in DLB including GBA and inflammatory pathways, it will be necessary to develop robust animal models that capture the true neuropathologic and behavioral abnormalities of DLB, and to identify possible disease-specific

<table>
<thead>
<tr>
<th>Alzheimer disease neuropathologic change</th>
<th>NIA-AA none/low (Braak stage 0-II)</th>
<th>NIA-AA intermediate (Braak stage III-V)</th>
<th>NIA-AA high (Braak stage V-VI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lewy-related pathology</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diffuse neocortical</td>
<td>High</td>
<td>High</td>
<td>Intermediate</td>
</tr>
<tr>
<td>Limbic (transitional)</td>
<td>High</td>
<td>Intermediate</td>
<td>Low</td>
</tr>
<tr>
<td>Brainstem-predominant</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Amygdala-predominant</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Olfactory bulb only</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Substantia nigra neuronal loss to be assessed (as none, mild, moderate, and severe) in order to subclassify cases into those likely or not to have parkinsonism</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

molecular differences in α-synuclein, tau, and Aβ among DLB, PD, PD dementia, and AD. The latter includes characterization of possible molecular strains of misfolded or pathologic α-synuclein, posttranslational modifications in degradation and clearance processes, and transmission and propagation. It will be increasingly important to study protein interactions among α-synuclein, Aβ, and tau. Finally, there is an unmet need to characterize biological effects of identified genetic risk factors, including APOE, GBA, and SNGA, as well as to model and analyze gene–environment interactions.

In order to best advance DLB research, global harmonization efforts are required to create networks of researchers and research participants who share common platforms for data and biomarker collection, outcome measures for clinical–translational research, and shared terminology across language, cultures, and traditions. Consideration might be given to creating an international patient and caregiver association to serve as advocates for private and public funding; identifying obstacles to the pharmaceutical industry sponsoring DLB research; bridging relationships with the PD and AD world research communities; creating a plan for reimbursement for DLB clinical care, drugs/devices, and biomarkers; and increasing interdisciplinary and interprofessional communication regarding the challenges facing clinicians, patients, and caregivers. Finally, priority needs to be given to helping patients and carers to inform themselves about the disease, its prognosis, best available treatments, ongoing research, and how to get adequate support.

AUTHOR AFFILIATIONS
From the Institute of Neuroscience (I.G.M., J.-P.T., J.A., D.B., A. Thomas), Newcastle University, UK; Departments of Neurology (B.F.B.) and Radiology (K. Kantarci), Mayo Clinic (A.L.), Rochester, MN; Neuropathology Laboratory (D.W.; M. Murray) and Departments of Psychiatry and Psychology (T.J.F.), University of Pittsburgh, and Neuroscience (P.M., O.A.R.), Mayo Clinic, Jacksonville, FL; Brain and Mind Centre (G.H.), University of Sydney (S.L.), Australia; Department of Neurology (J.E.D.) and Center for Neurodegenerative Disease Research (V.M.Y.L., J.Q.T.), Perelman School of Medicine at the University of Pennsylvania (D.W., A.C.-P., J.B.T.), Philadelphia; Parkinson’s Disease and Mental Illness Research, Education and Clinical Centers (PADRECC and MIRECC) (D.W.), Philadelphia Veterans Affairs Medical Center, PA; Institute of Psychiatry, Psychology, and Neuroscience (D.A., D.J.), King’s College London, UK; Centre for Age-Related Diseases (D.A.), Stavanger University Hospital, Norway; Institute for Healthy Aging and Lifespan Studies (I-HeAL) (J.G.), Florida Atlantic University, Boca Raton; Medical College (C.G.B.), University of Exeter; Lewy Body Society (A.B.), Edinburgh, UK; Banner Sun Health Research Institute (T.G.B.), Sun City, AZ; University Hospital of Strasbourg (F.B.); ICube Laboratory (F.B.); OMR2 Geriatrics Department and University of Strasbourg-CNRS, France; Departments of Radiology & Neurology (N.B.), University of Michigan; Department of Veterans Affairs (N.B.), Ann Arbor, MI; Department of Neuroscience, Imaging and Clinical Sciences (I.B.), University G. d’Annunzio of Chieti-Pescara, Chieti, Italy; Department of Molecular Neuroscience (J.B.), Institute of Neurology, UCL, London, UK; Center for Neurodegenerative Science (P.B.), Van Andel Research Institute, Grand Rapids, MI; Neurological Disorders Research Center (O.E.-A.), Qatar Biomedical Research Institute (QBRI), At-Rayyan; Department of Neurosciences (H. Feldman, D.G., D.P.S.), University of California, San Diego, Department of Psychiatry (H. Fujishiro), Nagoya University Graduate School of Medicine, Japan; Department of Neurological Sciences (J.G.G.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.N.G.), Mass General Institute for Neurodegenerative Disease, Massachusetts General Hospital, Boston; Department of Neurology and Taub Institute (L.S.H.), Columbia University, New York, NY; Neurology Service (A.S.), Hospital Clinic de Barcelona, Spain; Departments of Neurology and Psychiatry (A.K.), University of North Carolina at Chapel Hill; Department of Epidemiology (M.K.), University of Washington, Seattle; Lou Ruvo Center for Brain Health (J.B.L.), Neurologic Institute, Cleveland Clinic, OH; Thomas Jefferson University (C.L.), Philadelphia, PA; Department of Medicine (M. Maselli), Sunnybrook Health Sciences Centre, University of Toronto, Canada; Division of Neuroscience (E.M.), National Institute on Aging, Baltimore, MD; Paracelsus-Elenta-Klinik (B.M.), Kassel, Germany; Department of Pathology (T.F.M.), Stanford University, CA, GE Healthcare (E. Moreno), Medical Affairs, London, UK; Department of Behavioral Neurology and Cognitive Neuroscience (E. Morl), Tohoku University Graduate School of Medicine, Sendai, Japan; Department of Psychiatry (J.T.O.), University of Cambridge, UK; Department of Neurology (S.O.), Kanto Central Hospital, Tokyo, Japan; Department of Neurology (R.B.P.), Montreal General Hospital, Canada; Axovant Sciences, Inc. (S.R.), New York, NY; Laboratory of Neurogenetics (A.S.), NIH, Bethesda, MD; Lewy Body Dem dementia Association (A. Taylor), Lilburn, GA; Neurology Department (J.B.T.), Houston Methodist Hospital, TX; Division of Neurology/Neuropathology (P.T.), Fondazione IRCCS, Istituto Neurologico Carlo Besta, Milan, Italy; VA Puget Sound Health Care System (D.T.), Seattle, WA; University College London & North Essex Partnership University NHS Foundation Trust (Z.W.), UK; Department of Neurology and Neurosurgery (A.Y.), Kanazawa University Graduate School of Medical Sciences, and Yokohama City University Medical Center (K. Konaka), Japan.

AUTHOR CONTRIBUTIONS
Ian McKhod: design or conceptualization of the study, analysis or interpretation of the data, drafting or reviewing the manuscript. Bradley Boeve: design or conceptualization of the study, analysis or interpretation of the data, drafting or reviewing the manuscript. Dennis Dickson: design or conceptualization of the study, analysis or interpretation of the data, drafting or reviewing the manuscript. Daniel Weintraub: design or conceptualization of the study, analysis or interpretation of the data, drafting or reviewing the manuscript. David Aarsland: design or conceptualization of the study, analysis or interpretation of the data, drafting or reviewing the manuscript. John-Paul Taylor: design or conceptualization of the study, analysis or interpretation of the data, drafting or reviewing the manuscript. Frédéric Blanc: analysis or interpretation of the data, drafting or revising the manuscript. Clive Ballard: analysis or interpretation of the data, drafting or reviewing the manuscript. Dennis Dickson: design or conceptualization of the study, analysis or interpretation of the data, drafting or reviewing the manuscript. John-Paul Taylor: design or conceptualization of the study, analysis or interpretation of the data, drafting or reviewing the manuscript. Jose Bras: design or conceptualization of the study, analysis or interpretation of the data, drafting or revising the manuscript. Thomas Beach: design or conceptualization of the study, analysis or interpretation of the data, drafting or reviewing the manuscript. Laura Bonanni: analysis or interpretation of the data, drafting or reviewing the manuscript. Nicolea Bohm: analysis or interpretation of the data, drafting or reviewing the manuscript. Maria De Pablo: analysis or interpretation of the data, drafting or reviewing the manuscript. Javad Babaei: analysis or interpretation of the data, drafting or reviewing the manuscript. Maryam Sajjadi: analysis or interpretation of the data, drafting or reviewing the manuscript. Omer Al-Agha: analysis or interpretation of the data, Howard Feldman: design or conceptualization of the study, analysis or interpretation of the data, drafting or reviewing the manuscript. Tanis Ferman: design or conceptualization of the study,
analysis or interpretation of the data, drafting or revising the manuscript. Dominique Flythe: analysis or interpretation of the data. Hiroshige Fujishiro: design or conceptualization of the study, analysis or interpretation of the data. Douglas Galasko: analysis or interpretation of the data, drafting or revising the manuscript. Neill R. Graff-Radford: design or conceptualization of the study, analysis or interpretation of the data, drafting or revising the manuscript. Lawrence S. Honig: analysis or interpretation of the data, drafting or revising the manuscript. Alex Iancu: analysis or interpretation of the data, drafting or revising the manuscript. Kejal Kantarci: design or conceptualization of the study, analysis or interpretation of the data, drafting or revising the manuscript. Daniel Kaufer: analysis or interpretation of the data, drafting or revising the manuscript. Walter Kukull: design or conceptualization of the study, analysis or interpretation of the data, drafting or revising the manuscript. Simon Lewis: analysis or interpretation of the data, drafting or revising the manuscript. Carol Lippa: design or conceptualization of the study, analysis or interpretation of the data, drafting or revising the manuscript. Angela Lunde: design or conceptualization of the study, analysis or interpretation of the data, drafting or revising the manuscript. Manto Masliah: analysis or interpretation of the data, drafting or revising the manuscript. John O’Brien: design or conceptualization of the study, analysis or interpretation of the data, drafting or revising the manuscript. Satoshi Otsu: analysis or interpretation of the data, drafting or revising the manuscript. Thomas Montine: analysis or interpretation of the data, Emilio Moreno: analysis or interpretation of the data, drafting or revising the manuscript. Etsuro Moto: analysis or interpretation of the data. Melissa Murray: analysis or interpretation of the data, drafting or revising the manuscript. John Trojanowski: analysis or interpretation of the data, drafting or revising the manuscript. Debby Tinsan: analysis or interpretation of the data, drafting or revising the manuscript. Zuzana Walker: design or conceptualization of the study, analysis or interpretation of the data, drafting or revising the manuscript. Masahito Yamada: analysis or interpretation of the data, drafting or revising the manuscript. Kenji Kosaka: analysis or interpretation of the data.

ACKNOWLEDGMENT

The authors thank Dr. Val Lowe, Mayo Clinic, Rochester, for FP-CIT SPECT and FDG-PET images (figures 1 and 4); and Dr. Kenichi Nakajima, Department of Nuclear Medicine, Kanazawa University, for SPECT and FDG-PET images (figures 1 and 4)."
and the International Parkinson and Movement Disorder Society; hono-
roraria from AbbVie, Acadia, Biogen, Boehringer-Ingelheim, Cerecor, \textit{et al.} have been involved in the preparation of this manuscript. N. Kantarci serves as a consultant to Alnylam Pharmaceuticals. He has received research support from the NIH, Janssen, Biogen, and several other companies. He is a member of the Scientific Advisory Board for Takeda Pharmaceuticals. He serves as a consultan
from Biote and Roche, and speaker fees from Novartis Canada and Teva Neurosciences. S. Ramaswamy is an employee of Axovant Sciences, Inc. He has been involved in the design and execution of the clinical trials in Lewy body dementia conducted by Axovant. O. Ross reports no disclosures relevant to the manuscript. D. Salmon is a consultant for Takeda Pharmaceuticals and is supported by NIA grant AG05131. A. Singleton is an employee of the Intramural Program of the NIH. A. Taylor is an employee of the Lewy Body Dementia Association. A. Thomas has received support from GE Healthcare, the manufacturer of 123I-FP-CIT (DaTSCAN), for investigator-led research. P. Tiraboschi reports no disclosures relevant to the manuscript. J. Toledo has received research support from Eli-Lilly. J. Trojanowski may accrue revenue in the future on patents submitted by the University of Pennsylvania wherein he is a coinventor on imaging-related patents submitted by the University of Pennsylvania. He receives research support from the NIH, GSK, Janssen, Biogen, and several nonprofits. D. Tsuang serves on the Editorial Board of the American Journal of Medical Genetics, Neuropsychiatric Section, and receives research funding from the NIH and Veteran Affairs Research and Development. Z. Walker has received funding for travel, consultancy, speaker fees, and research support from GE Healthcare (GEHC). M. Yamada received honoraria for sponsored lectures and research grant from Fujifilm RI Pharma Co. Ltd. K. Kosaka reports no disclosures relevant to the manuscript. Go to Neurology.org for full disclosures.

Received September 30, 2016. Accepted in final form March 30, 2017.

REFERENCES

Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium
Ian G. McKeith, Bradley F. Boeve, Dennis W. Dickson, et al.
Neurology 2017;89;88-100 Published Online before print June 7, 2017
DOI 10.1212/WNL.0000000000004058

This information is current as of June 7, 2017